Baird raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $31 from $28 and keeps an Outperform rating on the shares. the firm raised its target to reflect its favorable verdict on its Nuplazid patent that extends into 2038.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACADIA Pharmaceuticals’ Legal Victory and Pipeline Expansion Drive Buy Rating and Increased Price Target
- Acadia Pharmaceuticals price target raised to $32 from $27 at H.C. Wainwright
- Acadia court ruling alleviates overhang for Nuplazid, says RBC Capital
- Acadia confirms court ruling in favor of Nuplazid formulation patent
- ACADIA Pharmaceuticals: Strengthened Patent Position and Growth Prospects Drive Buy Rating